Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 25 April 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

The right idea for the wrong patient: results of a national survey on stopping PPIs

The Right Idea for the Wrong Patient: Results of a National Survey on Stopping PPIs

News image

Recent studies have linked proton pump inhibitor use to serious adverse effects, including bone fracture, chronic kidney disease, dementia, and ischemic stroke.

Although it remains unclear whether proton pump inhibitors truly cause these adverse effects, this potential has forced physicians to carefully consider the safety 
and utility of long-term PPI use in their patients, a topic included in the American Board of Internal Medicine Foundation’s Choosing Wisely campaign.

Using case vignettes, Dr Jacob Kurlander and colleagues from Michigan, USA evaluated internists’ willingness to stop proton pump inhibitor varies according to drug indication.

In 2013, the reseachers conducted an online, cross-sectional survey of a representative sample of the American College of Physicians using their Internal Medicine Insider Research Panel.
Respondents shown the high-risk vignette were 1.93 times more likely to stop proton pump inhibitor
Clinical Gastroenterology & Hepatology

Physicians spending 25% of their time in direct patient care were invited.

The research team developed 3 patient vignettes, all featuring a 70-year-old woman prescribed omeprazole, 20 mg daily, and recently diagnosed with osteopenia,  increasing her risk of bone fracture, a reported PPI adverse effect.

The vignettes differed in proton pump inhibitor indication:  gastroesophageal reflux disease  well controlled for years with normal upper endoscopy;  prevention of 
upper gastrointestinal bleeding  while on low-dose aspirin  and warfarin, otherwise asymptomatic; or  prevention of upper gastrointestinal bleeding while on low-dose 
aspirin alone with a history of nonsteroidal anti-inflammatory drug–related peptic ulcer disease 10 years prior, otherwise asymptomatic.

The 3 vignettes represented low-, moderate-, and high-risk for upper gastrointestinal bleeding, respectively, and bleeding risk was not explicitly stated in the vignettes.

Respondents were presented at random with 2 of the 3 patient vignettes to minimize respondent fatigue.

For each vignette, the researchers asked respondents how likely they would be to stop proton pump inhibitor on a 1–7 Likert-type scale.

The researchers also asked participants how concerned they were about long-term pump inhibitor indication adverse effects on a 1–7 Likert-type scale.

The reserchers hypothesized that physicians would be most likely to recommend proton pump inhibitor stopping in the patient with gastroesophageal reflux disease.

A total of 487 of 914 invited participants completed the survey. 

The team found that the median age was in the 5th decade of life, and 30% were female.

The researchers noted that a total of 22% were trainees, 58% practiced general medicine, 2% gastroenterology, and 18% another subspecialty.

The team observed that on a 1–7 scale, most physicians reported moderate concern about PPI adverse effects.

For the patient vignette with high risk for upper gastrointestinal bleeding , 62% of respondents would stop the proton pump inhibitor, compared with 47% for the 
moderate-risk vignette, and only 32% for the low-risk vignette.

The team noted that respondents shown the moderate-risk vignette were 1.47 times  more likely to stop proton pump inhibitor relative to the low-risk vignette, whereas respondents shown the high-risk vignette were 1.93 times more likely to stop proton pump inhibitor relative to the low-risk.

Dr Kurlander's team concludes,  "For every 1-point increase on the 7-point scale of concern about proton pump inhibitor adverse effects, probability of stopping proton pump inhibitor increased by 11%."

"Older physician age  and being a current trainee  were both independently associated with a lower probability of stopping." 

Clin Gastroenterol Hepatol 2017: 15: 1475–1476
14 September 2017

Go to top of page Email this page Email this page to a colleague

 25 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
PPI and risk of stroke
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 23 April 2018 
Sleep deprivation and NAFLD in the USA
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 20 April 2018 
Two annexin A11 epitopes targeted by IgG1 and IgG4 autoantibodies were shared between patients with IAC/AIP and IgG4 antibodies blocked binding of IgG1 antibodies to the shared annexin A11 epitopes
 20 April 2018 
Obesity and physical activity in diverticulosis
 20 April 2018 
Adalimumab with azathioprine in Crohn's
 20 April 2018 
Worldwide H.pylori prevalence
 19 April 2018 
Fibrosis in patients with chronic hepatitis B
 19 April 2018 
c-Myc expression and pancreatic cancer
 19 April 2018 
Olmesartan prescription in the USA
 18 April 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 18 April 2018 
Hep C treatment for sustained virologic response
 18 April 2018 
Endoscopic necrosectomy reduces risk of death 
 17 April 2018 
Colorectal cancer screening and ethnic inequities
 17 April 2018 
Training programs should consider radiation education for advanced endoscopy fellows
 17 April 2018 
Aspirin and pancreatic cancer
 16 April 2018 
Surgery for colorectal polyps has increased 
 16 April 2018 
Advanced fibrosis can be ruled out in primary health care patients
 16 April 2018 
Antibiotic use and colorectal adenoma
 13 April 2018 
Colorectal cancer cell lines
 13 April 2018 
Infliximab and corticosteroid-free clinical remission in Crohn's
 13 April 2018 
Teduglutide for children with short bowel syndrome
 12 April 2018 
Prescriptions for opiate drugs amongst primary care patients with IBD
 12 April 2018 
Lower GI bleeding related to comorbidity
 12 April 2018 
non–Clostridium difficile bacterial infections in IBD
 11 April 2018 
Bile acid deficiency in IBS 
 11 April 2018 
Stem cell therapy for fistulas in Crohn's
 11 April 2018 
Physician perception of IBD trial results
 10 April 2018 
Overweight in childhood and type 2 diabetes
 10 April 2018 
immunoglobulin G associates with clinical features of IBD
 10 April 2018 
T-cells repertoires in celiac disease
 09 April 2018 
Biomarker tests for colorectal cancer screening
 09 April 2018 
Fecal transplantation in C. difficile infection and treatment outcome 
 09 April 2018 
No weigh-loss drug improved all cardiometabolic risk factors
 06 April 2018 
Colonoscopy and colorectal cancer mortality
 06 April 2018 
Eosinophilic esophagitis and health-related quality of life
 05 April 2018 
Laparoscopic Nissen fundoplication for GERD treatment
 05 April 2018 
Random biopsies for neoplasia in IBD
 04 April 2018 
Alpha‐1 antitrypsin deficiency and liver disease
 04 April 2018 
Adjuvant chemotherapy for advanced colon cancer
 29 March 2018 
Prevention of metachronous gastric cancer
 29 March 2018 
Acute lower GI bleeding
 28 March 2018 
Decision aid used by IBD patients
 28 March 2018 
Transition for young adults with IBD
 28 March 2018 
Amitriptyline in functional dyspepsia
 27 March 2018 
Emergency department utilization for IBD 
 27 March 2018 
Management of hemorrhoids in the USA
 27 March 2018 
Adult ulcerative colitis
 26 March 2018 
Biological therapy response in IBD 
 26 March 2018 
Obesity and diverticulosis
 26 March 2018 
Practice guidelines for chronic constipation
 23 March 2018 
Health-related quality of life in eosinophilic esophagitis
 23 March 2018 
Genetics and chronic liver disease
 23 March 2018 
Global prevalence of H.pylori

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us